The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment

Yajing Mi†, Na Guo†, Jing Luan†, Jianghong Cheng†, Zhifang Hu†, Pengtao Jiang†, Weilin Jin1,2* and Xingchun Gao1,2*

1 Shaanxi Key Laboratory of Brain Disorders, Institute of Basic Medical Sciences, Xi’an Medical University, Xi’an, China. 2 Key Lab for Thin Film and Microfabrication Technology, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Institute of Nano Biomedicine and Engineering, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid progenitor and precursor cells at different stages of differentiation, which play an important role in tumor immunosuppression. Glioma is the most common and deadliest primary malignant tumor of the brain, and ample evidence supports key contributions of MDSCs to the immunosuppressive tumor microenvironment, which is a key factor stimulating glioma progression. In this review, we summarize the source and characterization of MDSCs, discuss their immunosuppressive functions, and current approaches that target MDSCs for tumor control. Overall, the review provides insights into the roles of MDSC immunosuppression in the glioma microenvironment and suggests that MDSC control is a powerful cellular therapeutic target for currently incurable glioma tumors.

Keywords: MDSC, glioma, immunosuppression, tumor microenvironment, therapeutic target

INTRODUCTION

Glioma is the most common primary malignant tumor of the brain, and is characterized by high proliferation rates, and migration and invasion abilities. Comprehensive treatment includes surgical resection combined with radiotherapy and chemotherapy; however, such approaches are generally ineffective. The median survival time of patients with the most malignant glioma is approximately 1–2 years despite aggressive therapy, including surgery, radiotherapy and chemotherapy (1). Hence, development of more effective treatments is urgently required. Recently, immunotherapeutic approaches have been developed for cancer therapy, with exciting progress for some cancers; however, there are specific challenges for glioma immunotherapy (2). Many factors may contribute to these difficulties, including the blood-brain barrier (BBB), antigenic and genetic heterogeneity, and the tumor microenvironment (TME).

THE IMMUNE MICROENVIRONMENT IN GLIOMA

The TME is the dynamic milieu of a tumor, including the extracellular matrix (ECM), signaling molecules, stromal cells, and immune cells, which influence the growth and evolution of tumor cells. The glioma microenvironment differs from other solid tumors, because gliomas are located...
in the brain, which is an immune privileged organ, protected by the BBB, where cells of the peripheral immune system are prevented from entering under normal conditions. However, inflammation and tumor growth can disrupt the BBB (3, 4). The strong immunosuppressive TME of gliomas has led them to be referred to in the literature as “cold tumors” (5). Many studies have demonstrated that cytokines, chemokines, and regulatory immune-suppressive cells (6, 7), such as TGF-κB, IL-10, prostaglandin E2, NK T cells, T/B regulatory cells (T/Bregs), tumor-associated macrophages/microglia (TAMs), and myeloid-derived suppressor cells (MDSCs) (8), create a specific immunosuppressive TME, which is important for anti-tumor responses and glioma progression. All these proved that MDSCs are powerful inhibitors of anti-tumor immune responses in glioma, hence targeting MDSCs will be beneficial for patients with these tumors. Here, we review the phenotypic characteristics of MDSCs, as well as their mechanisms of development and activation, and strategies for MDSC-depletion.

**SOURCE AND CHARACTERIZATION OF MDSCS**

Myeloid-derived suppressor cells are a heterogeneous group of myeloid progenitor and precursor cells, comprising macrophages, granulocytes, and dendritic cells (DCs) at different stages of differentiation. In healthy individuals, immature myeloid cells (IMCs) quickly differentiate into mature macrophages, granulocytes, or DCs (9); however, under pathological conditions, such as in patients with cancer, chronic inflammatory conditions prevent IMC differentiation into mature myeloid cells, resulting in MDSC accumulation (10). In cancer patients, MDSCs are defined as cells that co-express the myeloid differentiation markers, CD11b and CD33, while lacking markers of mature lymphoid and myeloid cells, such as the MHC class II molecule, HLA-DR (11). There are three main types of MDSCs: granulocytic or polymorphic nuclear MDSCs (G/PMN-MDSCs), mononuclear MDSCs (M-MDSC), and early-stage MDSCs (eMDSCs). In humans, M-MDSCs are characterized as CD11b+CD14+CD33+HLA-DRlow−CD15−, PMN-MDSCs as CD11b+CD14+CD33+HLA-DRlow−CD15+ (or CD66c+), and eMDSCs as Lin− (i.e., CD3−, CD14−, CD15−, CD19−, CD56−, HLA-DR−, and CD33+). In mouse, MDSCs are defined as cells that co-express CD11b and Gr-1 (12), where Gr-1 is a cell surface antigen, and can be divided into Ly6C and Ly6G. Hence, M-MDSCs are characterized as CD11b+, Ly6C+, Ly6G−, according to their relative expression levels of Ly6G and Ly6C, whereas PMN-MDSCs are CD11b+, Ly6C−, Ly6G+, and eMDSCs have yet to be defined.

In humans, M-MDSCs can be distinguished from monocytes based on the expression of the MHC class II molecule HLA-DR (13). The PMN-MDSCs and neutrophils can be separated on the base of their low-density properties when using a standard Ficoll gradient. Recently, Condamine T. et al. identified that lectin-type oxidized low-density lipoprotein receptor-1 (LOX-1) as a potential marker of human PMN-MDSC (12). Moreover, the M-MDSCs and PMN-MDSCs also display specific cell-death-associated program. Havercamp et al. demonstrated that the anti-apoptotic molecules c-FLIP [cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein] is required for monocytic MDSC development (14). Fiore et al. reported that c-FLIP can activate many transcription of several immunosuppression-related genes in part through nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) activation, and then plays an important role in re-programming monocytes into MDSCs without affecting cell survival, but not affects the conversion from neutrophils into PMN-MDSCs (15).

As we known, the basic functional characteristic of MDSCs is suppressing immune cells, mainly T-cells and lesser B and NK cells (16). Groth et al. reported that M-MDSCs showed a higher immunosuppressive capacity compared to PMN-MDSC, which directly suppress T cell function or induce the generation of Treg cells by secreting TGF-β and IL-10 (17). Trovato et al. showed that M-MDSCs are the most potent myeloid subset to halt T cell proliferation in patients with pancreatic ductal carcinoma (18). Moreover, plasticity and function of MDSCs are strictly regulated by the activation of specific molecular pathways (13), preferentially driven by signal transducer and activator of transcription 3 (STAT3), and CCAAT/enhancer binding proteinβ (C/EBPβ). Upregulation of STAT3 is a hallmark of MDSCs, which plays a central role in regulating MDSC expansion and tolerogenicity (19). Upregulation of C/EBP-β is also associated with the expansion of MDSCs populations (19). Furthermore, C/EBP-β controls the cells the immunosuppressive activity of MDSC through regulating the expression of arginase (ARG1) and inducible nitric oxide synthase (iNOS) (20, 21).

**MYELOID-DERIVED SUPPRESSOR CELLS IN GLIOMA**

Glioma is a central nervous system (CNS) tumor, and the immunosuppressive TME of glioma likely depends on depressed T cell function, through accumulation of immunosuppressive leukocytes, such as MDSCs and regulatory T-cells (Tregs). MDSCs number is usually relatively larger in the spleen, blood, and tumors, and correlates with the tumor stage and chemotherapy response (22). In glioma patients, the intratumoral density of MDSCs also increases during glioma progression and correlates with patient survival (23). Gielen et al. reported that MDSCs increased in blood samples from patients with glioma compared with healthy donors. (24) and Raychaudhuri et al. found that patients with glioblastoma multiforme (GBM) had elevated levels of MDSCs in their peripheral blood (25), and the majority of the MDSCs were neutrophilic CD15+CD14− (PMN-MDSC, 82%), followed by lineage-negative (eMDSCs, 15%), and monocytic (M-MDSC, 3%). Gielen et al. showed that MDSCs were significantly increased among peripheral blood mononuclear cells from patients with GBM, but only slightly and non-significantly increased in patients with grade II or III glioma, and MDSCs found in tumor material are almost exclusively CD15-positive (24). Dubinski et al. also revealed that the frequency of CD14highCD15pos M-MDSCs and CD14lowCD15pos PMN-MDSCs was significantly higher
in peripheral blood of GBM patients compared with healthy donors (26). These studies indicate the expansion of PMN and M-MDSC subtypes in patients with glioma, and M-MDSCs were the most abundant MDSC subpopulation in the blood, while PMN-MDSCs were dominant in glioma tissue. Further, Raychaudhuri et al. found that MDSCs represented 5.4 ± 1.8% of total cells in human GBM tumors; the majority were lineage negative (CD14<sup>−</sup>CD15<sup>−</sup>) eMDSCs, followed by PMN-MDSC (CD15<sup>+</sup>CD14<sup>+</sup>), and M-MDSC (CD15<sup>−</sup>CD14<sup>−</sup>) subtypes. In murine GBM tumors, MDSCs comprised 8.06 ± 0.78% of total cells, of which more were M-MDSC than G-MDSC (27). Hence, it is established that the types of MDSCs differ in tumor tissues compared with the circulation (blood), while detection of the predominant MDSC type in glioma requires further research, since the TME may impact MDSC migration or differentiation.

**MDSC EXPANSION AND RECRUITMENT**

Myeloid-derived suppressor cells are present at relatively low levels under normal conditions, but are recruited and differentiate in various pathologic situations, such as during autoimmune encephalitis, bacterial infections, and tumors. Jennifer et al. reported that the healthy donor human CD14<sup>+</sup> monocytes could acquire MDSC phenotypes (reduced CD14 not CD11b expression) and immunosuppressive properties (increased immunosuppressive interleukin-10, transforming growth factor-β (TGF-β), and B7-H1 expression) when cultured with human glioblastoma cell lines (28). Kumar et al. also found that normal human monocytes could become M-MDSCs when cultured in glioma-conditioned media under hypoxic conditions (29).

A variety of inflammatory mediators can induce MDSC expression and recruitment (Figure 1). Jiang et al. reported that interleukin-6 (IL-6) can promote the amplification and immunosuppressive function of breast cancer MDSCs in vitro and in vivo, by inducing dysfunction of SOCS3 and activation of signal transducer and transcription activator 3 (STAT3)-signaling (30). Gielen et al. reported that STAT3 also regulates MDSC amplification through expression of S100A8/9 in gliomas (31). Tumor-derived granulocyte macrophage colony-stimulating factor (GM-CSF) has an important role in the expansion of MDSCs, both in vitro and in vivo (32–34). Importantly, Marigo et al. found that GM-CSF and IL-6 allowed rapid and efficient generation of MDSCs from precursors present in mouse and human bone marrow (35). Moreover, various other tumor-derived factors, such as prostaglandin-E2 (PGE2) (36), IL-10 (37), VEGF (38), and TGF-β (39–41), have been suggested to contribute to the induction and expansion of MDSCs (36), and these factors are also derived from glioma cells. Albulescu et al. showed that IL-6, IL-1β, TNF-α, IL-10, VEGF, FGF-2, IL-8, IL-2, and GM-CSF were upregulated in gliomas (42). Further, many studies have shown that PGE2 is overexpressed in glioma (43). Together, these data suggest that glioma cells can stimulate the expansion of MDSCs by secreting numerous well-studied factors (IL-6, IL-10, VEGF, PGE2, GM-CSF, and TGF-β 2).

Chemokines are a family of 8–14 kDa chemoattractant cytokines secreted by cells, which have important roles in regulating cells trafficking (44). Multiple chemokines are involved in recruiting MDSCs in different cancer models (45–47). Chemokine (C-C motif) ligand (CCL) 2 and its receptors, chemokine (C-C motif) receptor (CCR) 2, 4, and 5, have key roles in attraction of M-MDSCs (48, 49). In particular, microenvironment-derived CCL-2 can recruit MDSCs to cancer sites via CCL2-CCR2 interaction (50). Furthermore, Vakilian et al. reviewed the CCL2/CCR2 signaling pathway in glioma and found that it plays a dual role in mediating early tumor immunosurveillance and sustaining tumor growth and progression (51). IL-8 (CXCL8) is a pro-inflammatory chemokine produced by many cell types, including glioma, and can promote MDSC trafficking into the tumor microenvironment through the IL-8/IL-8R axis (52, 53). CXC chemokine ligand 2 (CXCL2), also referred to as macrophage inflammatory protein-2 (MIP-2), has a pivotal role in recruiting MDSCs to tumor stroma (54). Kammerer et al. found that CXCL2 was an immune response gene in glioma; however, whether expression of this gene is altered in tumor cells or in the TME was not determined (55). Interestingly, Bruyère et al. found that inhibition of CXCL2 expression in Hs683 glioma cells using siRNA markedly impaired cell proliferation (56). Overall, these results suggest that high levels of CXCL2 expression are important for glioma progression; however, the mechanism regulating MDSC recruitment requires clarification.

**MDSC-INDUCED IMMUNOSUPPRESSION IN GLIOMAS**

Myeloid-derived suppressor cells indisputably induce immunosuppression and promote tumor development. Numerous mechanisms by which MDSCs inhibit immune responses have been reported, inducing inhibition of the anti-tumor activity of cytotoxic T cells, suppression of NK cell, macrophage, and dendritic cell (DC) function, and induction of Tregs and Bregs. In this section, we summarize the function of MDSCs in glioma development in detail (Figure 1).

**Inhibition of T Cell Function**

T cells, particularly cytotoxic T cells, have important roles in tumor-inhibition, and there is substantial evidence that MDSCs can inhibit T cell function via multiple mechanisms. MDSCs are well known to induce oxidative stress by secreting ROS and nitrogen species (RNS). The main pathways of ROS production are related to the NADPH oxidases (NOX) (57), and RNS are produced by the activation of ARG1 or INOS (NOS2) in different MDSC subsets (58). These reactive species can inhibit T cell growth through interfering with the expression of the CD3ζ chain and induction of apoptosis (59, 60). Moreover, intratumoral RNS production can inhibit the T cell migration by inducing the CCL2 chemokine nitration (61). MDSCs can also deplete metabolites and factors which are critical for T cell functions. MDSCs deplete L-arginine which inhibits T cell growth and induce
FIGURE 1 | MDSC recruitment and activation in glioma microenvironment. In the bone marrow, MDSCs originate from immature myeloid cells (IMC), and then expand and migrate to the glioma site through the interaction between CCR and respective chemokines (CCL). In the tumor microenvironment, MDSCs play immunosuppression role by inhibiting the anti-tumor activity of cytotoxic T cells, suppressing the NK, Macrophage and Dendritic cells (DCs) function, expansion, and promoting Tregs and Bregs.

Inhibiting NK Cell Function
NK cells are a critical component of innate immunity and can eradicate gliomas without T cell cooperation (68). Fortin et al. found that the MDSCs can suppress the function of NK cells via reactive oxygen species (ROS) production (69), while Li et al. showed that membrane-bound TGF-β1 on MDSCs can induce NK cell anergy (70). Further, Hoechst et al. reported that MDSCs suppress NK cell cytotoxicity and cytokine release through contact with the NK cell receptor, Nkp30 (71). Bruno et al. recently reviewed the interactions of MDSCs and NK cells and determined that cross-talk between these types of cells can impact tumor progression and angiogenesis (72).

Inhibiting Macrophage and DC Function
Microglia/macrophages are among the most common cells in brain tumors (73), and MDSCs can modulate functions of macrophages (74). Sinha et al. proved that cross-talk between...
MDSCs and macrophages skews macrophages toward an M2 phenotype by cell-cell contact, and decreases the production of IL-12 of macrophage (75). The downregulation of IL-12 is further exacerbated by the macrophages themselves, because the production of IL-10 of macrophages is also promoted by MDSCs (76). Interestingly, Pinton et al. found that the bone marrow-derived macrophages (BMDM) exerted a strong immunosuppression in the center of the glioma, but brain-resident microglial cells (MG) showed little or no suppression (77). So, the relationship between the MDSC and macrophages need further research in tumor especially glioma. DCs are the most powerful antigen-presenting cells and a DC vaccine has potential to improve clinical outcomes of patients with glioma (78, 79). Hu et al. proved that MDSCs can inhibit IL-12 production and suppress T cell stimulation of DCs through IL-10 production (80). These results suggest that MDSCs can regulate the functions of macrophages and DCs through different mechanisms.

**Targeting MDSCs in Glioma Therapy**

Elimination of MDSCs inhibits tumor progression by enhancing antitumor responses, and there are many reports that chemotherapy drugs can eliminate MDSCs. Suzuki et al. first proved that the chemotherapeutic drug, gemcitabine, can specifically reduce MDSCs, with no significant reductions in other immune cells, such as T cells, B cells, macrophages, or NK cells, in tumor-bearing animals (97). This immunomodulating capacity of gemcitabine could be useful to treat glioma (98). Otvos et al. showed that gemcitabine and 5-FU were selectively cytotoxic to MDSCs, with 5-FU showing greater efficacy in depleting MDSCs and inducing MDSC apoptosis in vitro and in vivo (99). Ugel et al. proved that gemcitabine and 5-FU mainly target M-MDSCs (100). Furthermore, low dose 5-FU can selectively deplete MDSCs, resulting in prolonged survival in a glioma mouse model (101). Recently, David et al. found that the orally bioavailable 5-FU produrg, capecitabine in combination with bevacizumab can reduce the circulating levels of MDSC in GBM patients (102). Many studies support a role for NF-related apoptosis-induced ligand receptors (TRAIL-Rs) act as potential targets for selective elimination of MDSCs (103). Dominguez et al. proved that DS-8273a, an agonistic TRAIL-R2 (DR5) antibody, could eliminate MDSCs without affecting lymphoid or mature myeloid cells (104), and Nagane et al. found that anti-DR5 mAb treatments significantly suppressed growth of subcutaneous glioma xenografts until complete regression (105). Murat et al. found that glioma patients with high expression of S100A8 and S100A9 are related with short survival (106). Recently, Qin et al. proved that S100A9 peptide-Fc fusion (pepti-body) reagents can deplete blood and splenic MDSCs in mouse tumor models (107, 108). Further, many researches proved that anti-IL-6 therapy showed potential benefits for treating various human cancers including glioma (109, 110), Sumida et al. found that an anti-IL-6 receptor monoclonal antibody (mAb) could eliminate MDSCs and inhibit tumor growth by enhancing T-cell responses, and that its therapeutic effect was enhanced by combination with gemcitabine (111). Together,
these data suggest that MDSCs can be directly depleted using various agents, including chemotherapy drugs, peptides, and mAbs; however, the mechanisms underlying MDSC elimination require further elucidation.

**Inhibition of MDSC Migration and Expansion**

Inhibiting MDSC migration and expansion is another strategy for tumor therapy. Glioma cells are known to secrete factors important for MDSC migration and expansion. Zhu et al. proved that systemic administration of neutralizing anti-CCL2 mAbs can block recruitment and decrease the number of MDSCs in the TME, providing significant survival benefits in mouse GL261 glioma and human U87 glioma xenograft models (112). Chen et al. reported that anti-VEGF antibody can effectively decrease the recruitment of MDSCs to tumor tissue (113), while anti-VEGF treatment has been proposed to enhance the survival and quality of life in glioma patients (114, 115). Many studies proved the protective effect of COX-2 inhibitors on glioma (116, 117), and the use of non-steroidal anti-inflammatory drugs was significantly associated with a lower risk of glioma (118, 119). Obermajer et al. demonstrated that inhibition of cyclooxygenase (COX-2) activity and PGE2 production can reduce the accumulation of human MDSCs in the ovarian cancer environment (45, 120). Sinha et al. proved that the COX-2 inhibitor, SC58236, delays primary tumor growth and reduces MDSC accumulation in spontaneously metastatic BALB/c-derived 4T1 mammary carcinoma mouse (121).

**Inactivation of MDSCs**

Once MDSCs migrate into the TME, they suppress anti-tumor responses via various mechanisms, hence impairment of MDSC activity is another strategy to target these cells. Increased production of NO and ROS facilitates MDSCs to suppress CD8+ T cell responses. The ROS scavenger, N-acetylcysteine (NAC), can inhibit MDSC function (108), while the NO scavenger, carboxy-PTIO (C-PTIO), can reduce the immunosuppressive activity of MDSCs and restore impaired CTL function by inhibiting the NO production (125). Activation of iNOS and ARG-1 also has key roles in MDSC activation. Phosphodiesterase-5 (PDE5) inhibitors include sildenafil, tadalafil, and vardenafil, they are emerged as a promising approach to inhibit proliferation, motility and invasion of certain cancer cells including glioma (126). These inhibitors are reported to suppress both iNOS and ARG-1 activities in MDSC, thereby decrease MDSC.
immunosuppressive functions (127, 128). Moreover, COX-2 is required for the production of PGE2 (129) and correlates positively with ARG-1 expression in MDSCs (130); hence, COX-2 inhibitors, such as celecoxib or acetylsalicylic acid, can suppress gliomagenesis by MDSC activation (131, 132). Entinostat (MS-275), a class I HDAC inhibitor in pre-clinical testing for glioblastoma, can inhibit MDSC function and exhibit antitumor effect in murine models of lung and renal cell carcinoma (133, 134).

It has been reported that the glutaminolysis contributes to MDSC function (135), this means glutamate metabolism (maintaining optimal glutamine or glutamate levels) is critical in MDSC-mediated immunosuppression phenomenon. As we know, glutamate is one of the main excitatory neurotransmitters in the central nervous system (CNS) (136). And in glioma microenvironments, the glutamate concentration is 400 times that of normal brain tissue (137). This high glutamate concentration is benefit for glioma cell growth and affects MDSCs function, so inhibition of glutamine metabolism is suggested as an attractive and druggable therapeutic target especially in glioma (138). The glutamine dehydrogenase inhibitor, epigallocatechin gallate (EGCG), which has been proved to induce apoptosis and inhibit proliferation of glioma cell (139), also could reverse MDSC activity (140).

Promotion of MDSC Differentiation

Promotion of MDSC differentiation into mature myeloid cells is a simple approach to inhibition of the immune-suppressive functions of MDSCs. All-trans retinoic acid (ATRA), a natural oxidative metabolite of vitamin A, can promote differentiation of MDSCs into mature myeloid cells (141). Mirza et al. reported that patients with cancer treated with ATRA exhibit improved myeloid/lymphoid DC ratios and immune responses (142). Further, Nefedova et al. found that the ATRA can active ERK1/2 MAPK signaling pathway, which increases the production of glutathione and reduces ROS levels, thus promoting MDSC differentiation (143). Recently, wang et al. proved that ATRA can induce asymmetric division of GSCs from the U87MG cell line, suggesting a therapeutic potential for glioma (144, 145). Similar to ATRA, vitamin D3 can induce immature MDSCs to be differentiated into dendritic and macrophages, and then displays anti-proliferative effects in a wide variety of cancer types including glioblastoma multiforme (GBM), (146–148). Moreover, Pan et al. proved that stem-cell factor (SCF), which is secreted by various cancers, including glioma (149), can decrease MDSC differentiation, resulting in MDSC expansion, while inhibiting SCF expression using siRNA can reduce MDSC accumulation (150).

CONCLUSION AND FUTURE PROSPECTS

To date, immunotherapeutic strategies have proven to be effective against various tumors, and researchers are increasingly focusing on immunotherapy for patients with glioma. Although significant progress has been made, some challenges must be overcome (7). There is substantial evidence that MDSCs are important immunosuppressors (11), hence targeting MDSC immune suppressive features has potential as an anti-tumor therapy approach in glioma (151); however, the mechanisms underlying MDSC activity in glioma require further elucidation. In recent years, several strategies have been investigated, such as elimination of MDSCs, inhibition of MDSC migration and expansion, inactivation of MDSCs, and promotion of MDSC differentiation. In summary, control of MDSCs is a powerful cellular therapeutic target for patients with glioma; nevertheless, further basic and clinical research is required in this field.

AUTHOR CONTRIBUTIONS

YM, NG, and JL conceived and structured the manuscript. JC, ZH, and PJ drafted the manuscript and figure. XG evaluated and reviewed the manuscript structure, ideas, and science. WJ conceived the topic and revised the manuscript. All authors read and approved the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (Nos. 81873740 and 81601376), Shaanxi Youth Talents Project, Scientific Research Program funded by the Shaanxi Provincial Education Department (No. 19JS057), Natural Science Basic Research Plan in Shaanxi Province of China (Nos. 2020JQ-879 and 2020JQ-877), Xi’an Medical University’s Key Disciplines of Molecular Immunology and Foundation of Xi’an Medical University’s (Nos. 2018GFYY05, 2018DOC02, 2018PT08, 18NBZD08, and 18NBZD09), and the Youth Innovation Team of Shaanxi Universities.

REFERENCES

1. Davis FG, McCarthy BJ. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther. (2001) 3:395–401. doi: 10.1586/1469-7580.2002. 00065.x

2. Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. (2018) 24:5198–205. doi: 10.1158/1078-0432.CCR-17-2769

3. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. (2002) 6:639–46. doi: 10.1046/j.1469-7580.2002. 00065.x

4. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. (2002) 1:85–91. doi: 10.1007/s00401-002-0524-x

5. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res. (2019) 14:4202–10. doi: 10.1158/1078-0432.CCR- 18-1627

6. Perug P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at Non-CNS sites. Front Oncol. (2015) 5:153. doi: 10.3389/fonc.2015. 00153
42. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, et al. Cytokine patterns in brain tumour progression. Med Inflamm. (2013) 2103:979748. doi: 10.1155/2013/979748

43. Mattila S, Tuominen H, Koivukangas J, Stenback F. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Neuropathology. (2009) 2:156–65. doi: 10.1111/j.1440-1799.2008.00963.x

44. Umanovsky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. (2016) 4:436. doi: 10.3390/vaccines4040036

45. Obermayer N, Muthuswamy R, Ondrus K, Edwards RP, Kalinski P. PGE2(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. (2011) 24:7463–70. doi: 10.1158/0008-5472.CAN-11-2449

46. Connolly MK, Mallen-St Clair J, Bedrossian A, Malhotra A, Vera V, Ibrahim J, et al. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumors. J Leuk Biol. (2010) 4:713–25. doi: 10.1186/jlb.0909607

47. Wang SW, Liu SC, Sun HL, Huang TY, Chan CH, Yang CY, et al. CCL5/CXCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. (2015) 1:104–14. doi: 10.1095/carcin/bgu218

48. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Connolly MK, Mallen-St Clair J, Bedrossian A, Malhotra A, Vera V, Ibrahim J, et al. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumors. J Leuk Biol. (2010) 4:713–25. doi: 10.1186/jlb.0909607

49. Zhang J, Patel I, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytok Growth Fact Rev. (2010) 1:41–8. doi: 10.1016/j.ctogfr.2009.11.009

50. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. (2016) 19:5671–82. doi: 10.1158/0008-5472.CAN-16-11792

51. Vakilian A, Khorrormedelazad H, Heidari P, Sheikh Rezaei Z, Hassanshahi G. CCL2/CXCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. (2017) 103:1–7. doi: 10.1016/j.neuint.2016.12.013

52. Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed MF, Andueza MP, et al. Monocytic CCR2+ myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen metabolites. Front Immunol. (2016) 1:587. doi: 10.3389/fimmu.2016.00587

53. Fortin C, Huang X, Yang Y. NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J Immunol. (2012) 4:275–81. doi: 10.1016/j.semcancer.2012.01.011

54. Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, et al. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. (2014) 18:5079–90. doi: 10.1158/0008-5472.CAN-14-1203

55. Hoechst B, Voigtlaer T, Orlandy L, Gamrekashvili J, Zhao F, Medemeyer H, et al. Myeloid-derived suppressor cells interact with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. (2019) 10:771. doi: 10.3389/fimmu.2019.00771

56. da Fonseca AC, Badie B. Microglia and macrophages in malignant gliomas: recent discoveries and implications for promoting therapies. Clin Dev Immunol. (2013) 2013:264124. doi: 10.1155/2013/264124

57. Won WJ, Deshane JS, Leavenworth JW, Oliva CR, Griguer CE. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma. Cell Stress. (2019) 2:47–65. doi: 10.15698/cst2019.02.176

58. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells and myeloid cells by tumours. Nat Rev Cancer. (2015) 15:799–807. doi: 10.1038/nrc3954

59. Pinto L, Masetto E, Vettore M, Solito S, Magri S, D’Andolfi M, et al. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. (2019) 1:58. doi: 10.1186/s40425-019-0552-x

60. Marsh JC, Goldfarb J, Shafman TD, Diaz AZ. Current status of immunotherapy and gene therapy for high-grade gliomas. Cancer Cont. (2013) 1:43–8. doi: 10.1177/107327481302000107
97. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albeda SM. Geminibate selectively eliminates splenic Gr1-CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. (2005) 11:2565–74. doi: 10.1158/1078-0432.CCR-05-0883

98. Bastianich C, Bastiat G, Lagarce F. Geminibate and glialblastoma: challenges and current perspectives. Drug Discover Today. (2018) 2:416–23. doi: 10.1016/j.drudis.2017.10.010

99. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. (2010) 70:3502–11. doi: 10.1158/0008-5472.CAN-09-3690

100. Ugal S, Peranzoni E, Desantis G, Chiolda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. (2012) 5:468–78. doi: 10.1016/j.celrep.2012.08.006

101. Otros B, Silver D, Mukermans-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glialblastoma immune evasion. Stem Cells. (2016) 8:2026–39. doi: 10.1002/stem.2393

102. Peerboom DM, Alvan TJ, Grabowski MM, Alvarado AG, Otros B, Bayik D, et al. Metronomic capcitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. (2019) 4:e130748. doi: 10.1172/jci.insight.130748

103. Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finneberg N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Investig. (2014) 6:6266–39. doi: 10.1172/JCI74056

104. Murgat A, Migliavacca E, Hassin SF, Heimberger AB, Desbaillets I, Hamou M, et al. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. (2009) 4:e6594. doi: 10.1371/journal.pone.0006594

105. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. (2014) 6:676–81. doi: 10.1038/nm.3560

106. Alicea-Torres K, Gabrilovich DJ. Biology of myeloid-derived suppressor cells. In: Zitvogel L, Kroemer G editors. Oncoinflammation. Cham: Springer (2017).

107. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Cancer Res. (2015) 6:1248–57. doi: 10.1158/0008-5472.CAN-14-2291

108. Xue H, Yuan G, Guo X, Liu Q, Zhang J, Gao X, et al. A novel tumor-down-regulated myeloid derived suppressor cells contribute to hepato cellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. (2011) 5:254–60. doi: 10.3109/030056521.2010.516450

109. Bettelli E, Carrey R, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. (2006) 50:235–8. doi: 10.1038/nature04753

110. Oei TC, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA-101 expression. Cancer Cell. (2013) 4:409–21. doi: 10.1016/j.ccr.2004.08.031

111. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, et al. Inhibitory factor stimulates myeloid derived suppressor cell function and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. (2012) 8:2062–70. doi: 10.1002/eji.201142335

112. Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibodies in human glioma cells in vitro and in vivo. Exp Rev Neurother. (2013) 13:2021–31. doi: 10.1586/14737175.2013.857603

113. Chen XW, Sun JG, Zhang LP, Liao XY, Liao RX. Recruitment of CD115+ immature myeloid suppressor cells mediate the development of tumor-induced regulatory T cells and T-cell energy in tumor-bearing host. Cancer Res. (2006) 99:1211–30. doi: 10.1158/0008-5472.CAN-05-1299

114. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. CD115+ Gr-1+ myeloid-derived suppressor cells enhance stemness of cancer cells. PLoS One. (2011) 4:e16195. doi: 10.1371/journal.pone.0016195

115. Yagi L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr1CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. (2004) 4:409–21. doi: 10.1016/j.ccr.2004.08.031

116. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. (2008) 8:577–86. doi: 10.1038/nrc2371

117. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. (2008) 3:206–20. doi: 10.1016/j.ccr.2008.01.034

118. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the coexpressor CDP2. Immunity. (2013) 36:61–71. doi: 10.1016/j.immuni.2013.08.025

119. Peng D, Tanikawa T, Li W, Zhao L, Tatan L, Szeliga W, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6STAT3 and NOOTCH cross-talk signaling. Cancer Res. (2016) 11:3156–65. doi: 10.1158/0008-5472.CAN-15-2528

120. Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing pIRNA-823 expression and DNMT3B activation. Mol Cancer. (2019) 18:888. doi: 10.1186/s12943-019-1011-5

121. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albeda SM. Geminibate selectively eliminates splenic Gr1-CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. (2005) 11:6713–21. doi: 10.1158/1078-0432.CCR-05-0883

122. Bastianich C, Bastiat G, Lagarce F. Geminibate and glialblastoma: challenges and current perspectives. Drug Discover Today. (2018) 2:416–23. doi: 10.1016/j.drudis.2017.10.010

123. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. (2010) 83:3052–61. doi: 10.1158/0008-5472.CAN-09-3690

124. Ugald S, Peranzoni E, Desantis G, Chiolda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. (2012) 5:382–9. doi: 10.1016/j.celrep.2012.08.006

125. Otros B, Silver D, Mukermans-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glialblastoma immune evasion. Stem Cells. (2016) 8:2026–39. doi: 10.1002/stem.2393
factor 2 signaling pathway. *Anti Cancer Drugs*. (2020) 1:27–34. doi: 10.1097/ CAD.0000000000000825

118. Zhang T, Yang X, Liu P, Zhou J, Luo J, Wang H, et al. Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis. *Oncotarget*. (2017) 60:102486–98. doi: 10.18632/oncotarget.21829

119. Schreuer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antiangiogenic medication use and adult glioma risk. *Cancer Epidemiol Biomark Prev*. (2008) 5:1277–81. doi: 10.1158/1055-9966.EPI-07-2621

120. Condamine T, Mastio J, Gabrilovich D. Transcriptional regulation of myeloid-derived suppressor cells. *J Leu Biol*. (2015) 6:913–22. doi: 10.1189/jlb. RJ815104R

121. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. *Cancer Res*. (2007) 6:8507–13. doi: 10.1158/0008-5472.CAN-06-4174

122. Highfill SL, Cui Y, Giles AI, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci Trans Med*. (2014) 237:237ra267. doi: 10.1126/scitranslmed.3007974

123. Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. *JCI Insight*. (2019) 4:e126853. doi: 10.1172/jci.insight.126853

124. Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, et al. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK- and T-cell immunotherapy in head and neck cancer models. *Clin Cancer Res*. (2019) 26:1420–31. doi: 10.1158/1078-0432.CCR-19-2625

125. Hirano K, Hosoai A, Matsushita H, Iino T, Ueha S, Matsushima K, et al. The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. *Oncoimmunology*. (2015) 8:e1019195. doi: 10.2010/2162402X.2015.1019195

126. Barone I, Giordano C, Bonoffchio D, Ando S, Catalano S. Phosphodiesterase type 5 and cancers: progress and challenges. *Oncotarget*. (2017) 8:598179–202. doi: 10.18632/oncotarget.21837

127. Capuano G, Rigamonti N, Grioni M, Freschi M, Bellone M, Modulators of arginine metabolism support cancer immunosurveillance. *BMC Immunol*. (2009) 10:1. doi: 10.1186/1471-2474-10-1

128. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. *J Exp Med*. (2006) 12:2691–702. doi: 10.1084/jem.20061104

129. Lim JW, Kim H, Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. *Lab Investigat*. (2001) 3:349–60. doi: 10.1038/labinvest.3780243

130. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends Immunol*. (2011) 1:19–25. doi: 10.1016/j.it.2010.10.002

131. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-suppressor cell development. *Cancer Res*. (2011) 7:2664–74. doi: 10.1158/0008-5472.CAN-10-3055

132. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, et al. Myeloid suppressor cells and immune modulation in lung cancer. *Immunotherapy*. (2012) 3:291–304. doi: 10.2217/int.11.178

133. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Enotinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. *Clin Cancer Res*. (2017) 17:5817–20. doi: 10.1158/1078-0432.CCR-17-0741

134. Lee P, Murphy B, Miller R, Menon V, Banik NL, Giglio P, et al. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. *Anticancer Res*. (2015) 2:615–25.

135. Hammami I, Chen J, Bronte V, DeCrescenzo G, Jolicoeur ML. Glutamine is a key parameter in the immunosuppression phenomenon. *Biochem Biophys Res Commun*. (2012) 4:724–9. doi: 10.1016/j.bbrc.2012.07.139

136. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. *J Nutr*. (2000) 4:10075–10075

137. Robert SM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. *Cell Mot Life Sci CMLS*. (2014) 10:1839–54. doi: 10.1007/ s00018-013-1521-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Mi, Guo, Luan, Cheng, Hu, Jiang, Jin and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.